Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications.

The discovery of cardiac natriuretic hormones required a profound revision of the concept of heart function. The heart should no longer be considered only as a pump but rather as a multifunctional and interactive organ that is part of a complex network and active component of the integrated systems of the body. In this review, we first consider the cross-talk between endocrine and contractile function of the heart. Then, based on the existing literature, we propose the hypothesis that cardiac endocrine function is an essential component of the integrated systems of the body and thus plays a pivotal role in fluid, electrolyte, and hemodynamic homeostasis. We highlight those studies indicating how alterations in cardiac endocrine function can better explain the pathophysiology of cardiovascular diseases and, in particular of heart failure, in which several target organs develop a resistance to the biological action of cardiac natriuretic peptides. Finally, we emphasize the concept that a complete knowledge of the cardiac endocrine function and of its relation with other neurohormonal regulatory systems of the body is crucial to correctly interpret changes in circulating natriuretic hormones, especially the brain natriuretic peptide.

[1]  A. Ahluwalia,et al.  Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. , 2004, Basic research in cardiology.

[2]  H. Imura,et al.  Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. , 1987, Circulation.

[3]  G. Baxter Natriuretic peptides and myocardial ischaemia , 2004, Basic Research in Cardiology.

[4]  T. Yoshimoto,et al.  Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B. , 1994, The Journal of biological chemistry.

[5]  Sprenkle,et al.  Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. , 1993, The Journal of biological chemistry.

[6]  J. Winer,et al.  Phenylephrine, endothelin, prostaglandin F2alpha' and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro. , 1998, Endocrine.

[7]  M. Cowie,et al.  BNP and congestive heart failure , 2003 .

[8]  M. Esler,et al.  Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. , 2001, Journal of the American College of Cardiology.

[9]  R. Sarzani,et al.  The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. , 1998, Journal of nephrology.

[10]  G. Sagnella Review: Vasopeptidase inhibitors , 2002 .

[11]  H. Imura,et al.  Ventricular expression of atrial and brain natriuretic peptides in dilated cardiomyopathy. An immunohistocytochemical study of the endomyocardial biopsy specimens using specific monoclonal antibodies. , 1993, The American journal of pathology.

[12]  M. Redfield,et al.  Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. , 1998, American journal of physiology. Heart and circulatory physiology.

[13]  A. Wu,et al.  The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[14]  M. Emdin,et al.  Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure , 2004, Clinical chemistry and laboratory medicine.

[15]  A. Friedman,et al.  CORRELATION OF SERUM BRAIN NATRIURETIC PEPTIDE WITH HYPONATREMIA AND DELAYED ISCHEMIC NEUROLOGICAL DEFICITS AFTER SUBARACHNOID HEMORRHAGE , 2004, Neurosurgery.

[16]  D. Morrow,et al.  Brain Natriuretic Peptide Measurement in Acute Coronary Syndromes: Ready for Clinical Application? , 2002, Circulation.

[17]  H. H. Chen,et al.  C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. , 1998, Journal of cardiovascular pharmacology.

[18]  A. Takeshita,et al.  Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. , 2000, Journal of the American College of Cardiology.

[19]  H. Büller,et al.  Brain Natriuretic Peptide as a Predictor of Adverse Outcome in Patients With Pulmonary Embolism , 2003, Circulation.

[20]  D. Giannessi,et al.  Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. , 2000, Clinical chemistry.

[21]  S. Kawashima,et al.  PI 3-kinase-Akt-p70 S6 kinase in hypertrophic responses to leukemia inhibitory factor in cardiac myocytes. , 2003, The Kobe journal of medical sciences.

[22]  J. Waschek Developmental actions of natriuretic peptides in the brain and skeleton , 2004, Cellular and Molecular Life Sciences CMLS.

[23]  A. Balduini,et al.  Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis , 2003, Circulation.

[24]  A. Struthers,et al.  Vasopeptidase inhibitors in heart failure. , 2002, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[25]  M. Mehra,et al.  B-Type Natriuretic Peptide in Heart Transplantation: An Important Marker of Allograft Performance , 2003, Heart Failure Reviews.

[26]  A. Vollmar,et al.  Co-expression of the natriuretic peptides (ANP, BNP, CNP) and their receptors in normal and acutely involuted rat thymus , 1995, Journal of Neuroimmunology.

[27]  I. Hisatome,et al.  Interleukin-6 and tumor necrosis factor-alpha levels increase in response to maximal exercise in patients with chronic heart failure. , 2003, International journal of cardiology.

[28]  M. Sabatine,et al.  Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. , 2004, Journal of the American College of Cardiology.

[29]  G. Feuerstein,et al.  Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. , 1998, Journal of cardiovascular pharmacology.

[30]  K. Pandey Internalization and trafficking of guanylyl cyclase/natriuretic peptide receptor-A , 2005, Peptides.

[31]  J. Stewart,et al.  Contribution of the ventricles and the atrial appendages to the elevation of plasma atrial natriuretic factor (ANF) during pacing-induced heart failure in conscious dogs , 1996, Basic Research in Cardiology.

[32]  A. Siani,et al.  Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. , 2004, Obesity research.

[33]  A. Clerico Pathophysiological and Clinical Relevance of Circulating Levels of Cardiac Natriuretic Hormones: Are They Merely Markers of Cardiac Disease? , 2002, Clinical chemistry and laboratory medicine.

[34]  K. Yamaki,et al.  Plasma concentrations of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory diseases. , 1996, Chest.

[35]  J. Goetze Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. , 2004, Clinical chemistry.

[36]  S. Ogawa,et al.  Brain natriuretic peptide response is heterogeneous during β-blocker therapy for congestive heart failure , 2004 .

[37]  R. Bataller,et al.  Urinary excretion of urodilatin in patients with cirrhosis , 1996, Hepatology.

[38]  T. Fukutomi,et al.  Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. , 2004, The American journal of cardiology.

[39]  R. Ziegler,et al.  Neuromodulatory effects of atrial natriuretic factor are independent of guanylate cyclase in adrenergic neuronal pheochromocytoma cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[40]  M. Valença,et al.  Nitrergic modulation of vasopressin, oxytocin and atrial natriuretic peptide secretion in response to sodium intake and hypertonic blood volume expansion. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[41]  B. Johnson,et al.  Ectopic production and processing of atrial natriuretic peptide in a small cell lung carcinoma cell line and tumor from a patient with hyponatremia , 1997, Cancer.

[42]  K. Nakao,et al.  Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[43]  A. D. de Bold,et al.  Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. , 2004, Journal of molecular and cellular cardiology.

[44]  M. Horiuchi,et al.  Atrial natriuretic peptide and antihypertensive action due to beta-blockade in essential hypertensive patients. , 1995, Angiology.

[45]  S. Murray,et al.  Involvement of multiple cis elements in basal- and alpha-adrenergic agonist-inducible atrial natriuretic factor transcription. Roles for serum response elements and an SP-1-like element. , 1995, Circulation research.

[46]  M. Weinmann Natriuretic peptides and acute renal failure. , 1995, New horizons.

[47]  T. Matsuda,et al.  Local Expression of C-Type Natriuretic Peptide Suppresses Inflammation, Eliminates Shear Stress–Induced Thrombosis, and Prevents Neointima Formation Through Enhanced Nitric Oxide Production in Rabbit Injured Carotid Arteries , 2002, Circulation research.

[48]  R. Nohara,et al.  Neurohormonal determinants of peak oxygen uptake in patients with chronic heart failure. , 2003, Japanese heart journal.

[49]  T. Takano,et al.  Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. , 2005, International journal of cardiology.

[50]  S. Mudaliar,et al.  Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. , 2004, Journal of the American College of Cardiology.

[51]  K. Bailey,et al.  Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. , 2005, American heart journal.

[52]  R. McCuskey,et al.  Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[53]  H. Ruskoaho Cardiac hormones as diagnostic tools in heart failure. , 2003, Endocrine reviews.

[54]  R. Moreau,et al.  Blunted natriuresis and abnormal systemic hemodynamic responses to C-type and brain natriuretic peptides in rats with cirrhosis. , 1995, Journal of hepatology.

[55]  B. Chaitman,et al.  Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. , 2005, The American journal of cardiology.

[56]  H. Itoh,et al.  Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. , 1998, Journal of the American College of Cardiology.

[57]  S. Kruger,et al.  Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism , 2004 .

[58]  K. Margulies,et al.  ANF-mediated renal cGMP generation in congestive heart failure. , 1991, The American journal of physiology.

[59]  J. Rouleau,et al.  Vasopeptidase inhibitors: potential role in the treatment of heart failure. , 2001, Heart failure monitor.

[60]  K. Kangawa,et al.  Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. , 1998, American heart journal.

[61]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[62]  E. Levin,et al.  Natriuretic peptides inhibit rat astroglial proliferation: mediation by C receptor. , 1991, The American journal of physiology.

[63]  M. Hasumi,et al.  Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients: comparison of electrocardiography, chest radiography and echocardiography. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[64]  A. Vollmar,et al.  Immunomodulatory and cytoprotective function of atrial natriuretic peptide. , 2001, Critical reviews in immunology.

[65]  C. Zanker,et al.  Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. , 2002, Journal of the American College of Cardiology.

[66]  Y. Nakayama,et al.  Local Delivery of Single Low-Dose of C-Type Natriuretic Peptide, an Endogenous Vascular Modulator, Inhibits Neointimal Hyperplasia in a Balloon-Injured Rabbit Iliac Artery Model , 2002, Journal of cardiovascular pharmacology.

[67]  M. Hori,et al.  Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure , 2001, Journal of hypertension.

[68]  W. Forssmann,et al.  Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. , 1988, Circulation.

[69]  P. Bettencourt NT‐proBNP and BNP: biomarkers for heart failure management , 2004, European journal of heart failure.

[70]  H. Itoh,et al.  Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. , 1995, Circulation.

[71]  J. Pearlman,et al.  Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. , 2004, Journal of the American College of Cardiology.

[72]  M. D. de Bold,et al.  The physiological and pathophysiological modulation of the endocrine function of the heart. , 2001, Canadian journal of physiology and pharmacology.

[73]  A. Vollmar,et al.  Inhibition of cyclooxygenase-2 by natriuretic peptides. , 2002, Endocrinology.

[74]  Douglas L Mann,et al.  Stress-activated cytokines and the heart: from adaptation to maladaptation. , 2003, Annual review of physiology.

[75]  E. Topol Nesiritide - not verified. , 2005, The New England journal of medicine.

[76]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[77]  M. Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[78]  T. Tokudome,et al.  Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. , 2004, Metabolism: clinical and experimental.

[79]  F. Smith,et al.  The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. , 1976, The Journal of clinical investigation.

[80]  M. Quiñones,et al.  Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. , 2004, The American journal of cardiology.

[81]  M. Vogeser,et al.  Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[82]  R. Freeman,et al.  Captopril enhances renal responsiveness to ANF in dogs with compensated high-output heart failure. , 1992, The American journal of physiology.

[83]  Simon G. Williams,et al.  Comparison of plasma N-brain natriuretic peptide, peak oxygen consumption, and left ventricular ejection fraction for severity of chronic heart failure. , 2004, The American journal of cardiology.

[84]  K. Nakao,et al.  Cosecretion of peptides derived from gamma‐human atrial natriuretic polypeptide in normal volunteers and patients with essential hypertension and adrenal disorders , 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[85]  T. Horio,et al.  Stimulation of brain natriuretic peptide release from the heart by thyroid hormone. , 1993, Metabolism: clinical and experimental.

[86]  K. Imataka,et al.  Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. , 1987, Hypertension.

[87]  J. Marie,et al.  Le degré de granulation des cardiocytes auriculaires. Etude planimétrique au cours de différents apports d'eau et de sodium chez le rat , 1976 .

[88]  L. Wallentin,et al.  Natriuretic peptides in unstable coronary artery disease. , 2004, European heart journal.

[89]  J. Burnett,et al.  Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases , 2002, Circulation research.

[90]  M. Vatta,et al.  B and C Types Natriuretic Peptides Modify Norepinephrine Uptake and Release in the Rat Adrenal Medulla , 1997, Peptides.

[91]  B. Bruneau,et al.  Mechanical and neuroendocrine regulation of the endocrine heart. , 1996, Cardiovascular research.

[92]  K. Pandey Biology of natriuretic peptides and their receptors , 2005, Peptides.

[93]  D. Roth,et al.  Natriuretic peptide gene expression after beta-adrenergic stimulation in adult mouse cardiac myocytes. , 2004, DNA and cell biology.

[94]  M. Kuhn,et al.  Calcium-dependent Dephosphorylation Mediates the Hyperosmotic and Lysophosphatidic Acid-dependent Inhibition of Natriuretic Peptide Receptor-B/Guanylyl Cyclase-B* , 2004, Journal of Biological Chemistry.

[95]  P. McCullough,et al.  Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[96]  A. Gundlach,et al.  Ontogenic expression of natriuretic peptide mRNAs in postnatal rat brain: implications for development? , 1998, Brain research. Developmental brain research.

[97]  A. Vollmar,et al.  Expression and differential regulation of natriuretic peptides in mouse macrophages. , 1995, The Journal of clinical investigation.

[98]  R. Troughton,et al.  NT‐proBNP in heart failure: therapy decisions and monitoring , 2004, European journal of heart failure.

[99]  P. Ivarsen,et al.  A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. , 1997, Scandinavian journal of clinical and laboratory investigation.

[100]  K. Chien,et al.  Co-regulation of the atrial natriuretic factor and cardiac myosin light chain-2 genes during alpha-adrenergic stimulation of neonatal rat ventricular cells. Identification of cis sequences within an embryonic and a constitutive contractile protein gene which mediate inducible expression. , 1991, The Journal of biological chemistry.

[101]  P. Smits,et al.  Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. , 1993, Circulation.

[102]  D. Wilber,et al.  Retrograde fast pathway ablation for atrioventricular nodal reentry associated with markedly prolonged PR intervals. , 1999, The American journal of cardiology.

[103]  S. Graziano,et al.  Paraneoplastic syndromes associated with small cell lung cancer. , 1997, Chest surgery clinics of North America.

[104]  C. Johnston,et al.  Decreased Atrial Natriuretic Peptide Binding in Renal Medulla in Rats With Chronic Heart Failure , 1988, Circulation research.

[105]  M. Foschi,et al.  Blunted natriuretic response to low‐dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention , 1995, Hepatology.

[106]  M. Boscaro,et al.  Atrial natriuretic peptide in Cushing’s disease , 1990, Journal of endocrinological investigation.

[107]  B. Kisch Electron microscopy of the atrium of the heart. I. Guinea pig. , 1956, Experimental medicine and surgery.

[108]  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002 .

[109]  J. Born,et al.  Intranasal atrial natriuretic peptide acts as central nervous inhibitor of the hypothalamo-pituitary-adrenal stress system in humans. , 2004, The Journal of clinical endocrinology and metabolism.

[110]  M. Lapointe,et al.  Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. , 1999, Hypertension.

[111]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[112]  M. Horiuchi,et al.  Atrial Natriuretic Peptide and Antihypertensive Action Due to β-Blockade in Essential Hypertensive Patients , 1995 .

[113]  R. Potthast,et al.  Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptors , 2005, Peptides.

[114]  P. Urdal,et al.  Serum N-terminal pro-atrial natriuretic factor 1-98 before and during thyroxine replacement therapy in severe hypothyroidism. , 1997, Thyroid : official journal of the American Thyroid Association.

[115]  J. Tremblay,et al.  Alteration of lung atrial natriuretic peptide receptors in genetic cardiomyopathy. , 1996, The American journal of physiology.

[116]  A. Clerico,et al.  Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. , 2001, Clinical science.

[117]  Andrew,et al.  Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. , 1986, The Journal of clinical investigation.

[118]  G. Schreiner,et al.  B-Type Natriuretic Peptide Exerts Broad Functional Opposition to Transforming Growth Factor-&bgr; in Primary Human Cardiac Fibroblasts: Fibrosis, Myofibroblast Conversion, Proliferation, and Inflammation , 2004, Circulation research.

[119]  T. Takano,et al.  Plasma natriuretic peptide levels and daily physical activity in patients with pacemaker implantation. , 2001, Japanese heart journal.

[120]  A. Ahluwalia,et al.  Vascular actions of natriuretic peptides , 2004, Basic Research in Cardiology.

[121]  H. Rickli,et al.  Elevation of B-type natriuretic peptide levels in acute respiratory distress syndrome. , 2003, Swiss medical weekly.

[122]  F. Cappuccio,et al.  Raised plasma levels of atrial natriuretic peptides in Addison’s disease , 1989, Journal of endocrinological investigation.

[123]  D. Wilson,et al.  In vivo microperfusion of inner medullary collecting duct in rats: effect of amiloride and ANF. , 1990, The American journal of physiology.

[124]  A. Haramati,et al.  Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure. , 1990, The American journal of physiology.

[125]  J. Sadoshima,et al.  Negative regulators of cardiac hypertrophy. , 2004, Cardiovascular research.

[126]  T. Kato,et al.  Pathogenesis of hyponatremia following subarachnoid hemorrhage due to ruptured cerebral aneurysm. , 1996, Surgical neurology.

[127]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[128]  M. Vatta,et al.  B and C types natriuretic peptides modulate norepinephrine uptake and release in the rat hypothalamus , 1996, Regulatory Peptides.

[129]  H. Kanauchi,et al.  Resistance to Natriuresis in Patients with Peritonitis Carcinomatosa , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[130]  G. Palade,et al.  SPECIFIC GRANULES IN ATRIAL MUSCLE CELLS , 1964, The Journal of cell biology.

[131]  J. Rehfeld,et al.  Acute myocardial hypoxia increases BNP gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[132]  A. Struthers,et al.  Review: Vasopeptidase inhibitors in heart failure , 2002 .

[133]  R. Latini,et al.  Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. , 2002, Journal of cardiac failure.

[134]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.

[135]  M. McGrath,et al.  Determinants of natriuretic peptide gene expression , 2005, Peptides.

[136]  J. Winer,et al.  Phenylephrine, endothelin, prostaglandin F2α, and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro, and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro , 1998, Endocrine.

[137]  I. Hassinen,et al.  Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. , 1994, The American journal of physiology.

[138]  G. Iervasi,et al.  Alterations in metabolic clearance of atrial natriuretic peptides in heart failure: how do they relate to the resistance to atrial natriuretic peptides? , 1995, Journal of cardiac failure.

[139]  K. Werdan,et al.  Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction , 2003, Intensive Care Medicine.

[140]  E. Frohlich,et al.  Obesity and suppressed B-type natriuretic peptide levels in heart failure. , 2004, Journal of the American College of Cardiology.

[141]  K. Nakao,et al.  Effect of interleukin-1 beta on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. , 1999, Journal of molecular and cellular cardiology.

[142]  Robert,et al.  Co-regulation of the Atrial Natriuretic Factor and Cardiac Myosin Light Chain-2 Genes during a-Adrenergic Stimulation of Neonatal Rat Ventricular Cells , 2001 .

[143]  J. Kjekshus,et al.  Differential responses of plasma atrial and brain natriuretic peptides to acute alteration in atrial pressure in pigs. , 2000, Scandinavian journal of clinical and laboratory investigation.

[144]  N. Tamura,et al.  Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[145]  T. Marwick,et al.  Response of B-type natriuretic peptide to exercise in hypertensive patients with suspected diastolic heart failure: correlation with cardiac function, hemodynamics, and workload. , 2004, American heart journal.

[146]  R. Prywes,et al.  p38 Mitogen-activated Protein Kinase Mediates the Transcriptional Induction of the Atrial Natriuretic Factor Gene through a Serum Response Element , 1998, The Journal of Biological Chemistry.

[147]  D. Laky,et al.  Electronmicroscopic observations regarding the presence of natriuretic granules in the ventricle of patients with cardiopathies. , 1997, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[148]  P. Hildebrandt,et al.  N‐terminal‐pro‐B‐type natriuretic peptide (NT‐pro‐BNP) in different thyroid function states , 2004, Clinical endocrinology.

[149]  M. Tamaki,et al.  Molecular forms of human brain natriuretic peptide in plasma. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[150]  N. Alessandri,et al.  Plasma atrial natriuretic hormone in hyperthyroidism. , 1998, Endocrine research.

[151]  M. Kinoshita,et al.  Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. , 2001, Journal of the American College of Cardiology.

[152]  Eva Pietrzak,et al.  A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. , 2004, Archives of internal medicine.

[153]  S. Berti,et al.  Altered tissue degradation and distribution of atrial natriuretic peptide in patients with idiopathic dilated cardiomyopathy and its relationship with clinical severity of the disease and sodium handling. , 1995, Circulation.

[154]  A. Deten,et al.  Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. , 2002, Cardiovascular research.

[155]  R. Califf,et al.  Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) , 2002, Circulation.

[156]  M. Bold Estrogen, natriuretic peptides and the renin–angiotensin system , 1999 .

[157]  R. Zimmerman,et al.  Renal response to atrial natriuretic factor is modulated by intrarenal angiotensin II. , 1988, The American journal of physiology.

[158]  G. Sagnella Vasopeptidase inhibitors. , 2002, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[159]  H. Nawashiro,et al.  Focal brain edema and natriuretic peptides in patients with subarachnoid hemorrhage , 2004, Journal of Clinical Neuroscience.

[160]  C. Hennekens,et al.  Brain natriuretic peptide: a potential marker for mortality in septic shock. , 2004, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[161]  C. Benedict Neurohumoral aspects of heart failure. , 1994, Cardiology clinics.

[162]  M. Lapiński,et al.  Plasma atrial natriuretic peptide concentration in patients with primary aldosteronism. , 1991, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[163]  M. Emdin,et al.  Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. , 2004, Clinical chemistry.

[164]  A. Richards,et al.  BNP in hormone-guided treatment of heart failure , 2002, Trends in Endocrinology & Metabolism.

[165]  J. Rosado,et al.  Expression and control of C-type natriuretic peptide in rat vascular smooth muscle cells. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[166]  G. Brandenberger,et al.  Mechanisms of renal hyporesponsiveness to ANP in heart failure , 2003, European journal of clinical investigation.

[167]  J. Fray Endocrine regulation of water and electrolyte balance , 2000 .

[168]  A. Vollmar,et al.  Inhibition of p38 MAPK Activation via Induction of MKP-1: Atrial Natriuretic Peptide Reduces TNF-&agr;–Induced Actin Polymerization and Endothelial Permeability , 2002, Circulation research.

[169]  M. Andreassi,et al.  Up‐regulation of ‘clearance’ receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones , 2001, European journal of heart failure.

[170]  G. Ronnett,et al.  Atrial Natriuretic Peptide Type C Induces a Cell-Cycle Switch from Proliferation to Differentiation in Brain-Derived Neurotrophic Factor- or Nerve Growth Factor-Primed Olfactory Receptor Neurons , 2002, The Journal of Neuroscience.

[171]  N. Dalton,et al.  Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy , 2000, Basic Research in Cardiology.

[172]  J. Risteli,et al.  Atrial natriuretic peptide, B-type natriuretic peptide, and serum collagen markers after acute myocardial infarction. , 2004, Journal of applied physiology.

[173]  J. Herman,et al.  Distribution of natriuretic peptide precursor mRNAs in the rat brain , 1995, The Journal of comparative neurology.

[174]  M. Borggrefe,et al.  Prognostic Value of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients With Severe Sepsis , 2005, Circulation.

[175]  K. Sugita,et al.  Characterization of molecular forms of probrain natriuretic peptide in human plasma. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[176]  M. Anand-Srivastava Natriuretic peptide receptor-C signaling and regulation , 2005, Peptides.

[177]  M. Borggrefe,et al.  Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. , 2005, Clinical laboratory.

[178]  M. L. Kuroski de Bold Estrogen, natriuretic peptides and the renin-angiotensin system. , 1999, Cardiovascular research.

[179]  T. Ishizuka,et al.  Atrial natriuretic peptide inhibits tumor necrosis factor-alpha production by interferon-gamma-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B activation , 2001, Regulatory Peptides.

[180]  H. Nawata,et al.  Cardiovascular, renal and endocrine effects of alpha-human atrial natriuretic peptide in patients with Cushing's syndrome and primary aldosteronism. , 1989, Journal of hypertension.

[181]  I. Masuda,et al.  Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart. , 2000, American journal of physiology. Heart and circulatory physiology.

[182]  A. Richards,et al.  Dendroaspis natriuretic peptide: endogenous or dubious? , 2002, The Lancet.

[183]  K. Nakao,et al.  The natriuretic peptide system in the brain: implications in the central control of cardiovascular and neuroendocrine functions. , 1992, Frontiers in neuroendocrinology.

[184]  S. Goldhaber,et al.  Prognostic Role of Brain Natriuretic Peptide in Acute Pulmonary Embolism , 2003, Circulation.

[185]  T. Walther,et al.  Fibrosis rather than blood pressure determines cardiac BNP expression in mice , 2003, Regulatory Peptides.

[186]  M. Vogeser,et al.  Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. , 2004, American journal of respiratory and critical care medicine.

[187]  A. Vollmar,et al.  ANP inhibits TNF‐α‐induced endothelial MCP‐1 expression—involvement of p38 MAPK and MKP‐1 , 2003 .

[188]  J. Stypmann,et al.  Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. , 2004, Cardiovascular research.

[189]  F. Boomsma,et al.  Increased Plasma Concentration of Natriuretic Peptides by Selective &bgr;1-Blocker Bisoprolol , 2003, Journal of cardiovascular pharmacology.

[190]  M. Vatta,et al.  B-Type and C-Type Natriuretic Peptides Modify Norepinephrine Uptake in Discrete Encephalic Nuclei of the Rat , 2000, Cellular and Molecular Neurobiology.

[191]  U. Dahlström Can natriuretic peptides be used for the diagnosis of diastolic heart failure? , 2004, European journal of heart failure.

[192]  A. Torbicki,et al.  N‐terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism , 2003, European Respiratory Journal.

[193]  L. R. Potter,et al.  Down-Regulation Does Not Mediate Natriuretic Peptide-Dependent Desensitization of Natriuretic Peptide Receptor (NPR)-A or NPR-B: Guanylyl Cyclase-Linked Natriuretic Peptide Receptors Do Not Internalize , 2005, Molecular Pharmacology.

[194]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from Life Sci. 28:89-94, 1981. , 2001, Journal of the American Society of Nephrology : JASN.

[195]  G. Iervasi,et al.  Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. , 2000, Current drug metabolism.

[196]  M. Kurabayashi,et al.  Interleukin-6-Induced Reciprocal Expression of SERCA and Natriuretic Peptides mRNA in Cultured Rat Ventricular Myocytes , 2004, The Journal of international medical research.

[197]  S. Ogawa,et al.  Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure. , 2004, Journal of cardiac failure.

[198]  A. Vollmar,et al.  ANP inhibits TNF-alpha-induced endothelial MCP-1 expression--involvement of p38 MAPK and MKP-1. , 2003, Journal of leukocyte biology.

[199]  N. Arakawa,et al.  Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population , 2002, Heart.